Compared with placebo, simnotrelvir/ritonavir led to faster resolution of symptoms in vaccinated adults with mild-to-moderate COVID-19.
Nirmatrelvir/ritonavir (Paxlovid), a SARS-CoV-2 protease inhibitor, is first-line therapy for high-risk, non-hospitalized patients with COVID-19 (JAMA 2023; 330:1519). Now, investigators in China report the results of a placebo-controlled trial of another SARS-CoV-2 protease inhibitor, simnotrelvir/ritonavir, in adults with mild-to-moderate COVID-19 during the Omicron era.
In all, 1208 participants (median age, 35; 96% previously vaccinated against COVID-19) were randomized 1:1 to receive 5 days of simnotrelvir/ritonavir or placebo. About half had a risk factor for severe COVID-19 (mostly commonly overweight/obesity [36%]). Median time to sustained symptom resolution was 7.5 days (simnotrelvir) vs. 9 days (placebo). Simnotrelvir was also ass…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)